SEARCH

SEARCH BY CITATION

References

  • 1
    Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., Dawber, TR. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62: 70714.
  • 2
    von Eckardstein, A., Huang, Y., Assmann, G. (1994) Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 5: 404416.
  • 3
    Rader, DJ. (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest. 116: 30903100.
  • 4
    Ng, D. S., Leiter, L. A., Vezina, C., Connelly, P. W., Hegele, RA. (1994) Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest. 93: 223229.
  • 5
    Tilly-Kiesi, M., Lichtenstein, A. H., Ordovas, J. M., et al (1997) Subjects with ApoA-I(Lys107–>0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII). Arterioscler Thromb Vasc Biol. 17: 873880.
  • 6
    Chroni, A., Duka, A., Kan, H. Y., Liu, T., Zannis, VI. (2005) Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry. 44: 1435314366.
  • 7
    Mott, S., Yu, L., Marcil, M., Boucher, B., Rondeau, C., Genest, J. (2000) Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis. 152: 457468.
  • 8
    Francis, G. A., Knopp, R. H., Oram, JF. (1995) Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Invest. 96: 7887.
  • 9
    Albrecht, C., Baynes, K., Sardini, A., et al (2004) Two novel missense mutations in ABCA1 result in altered trafficking and cause severe autosomal recessive HDL deficiency. Biochim Biophys Acta. 1689: 4757.
  • 10
    Emmerich, J., Verges, B., Tauveron, I., et al (1993) Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. Arterioscler Thromb. 13: 12991306.
  • 11
    Williams, P. T., Haskell, W. L., Vranizan, K. M., Krauss, RM. (1995) The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: the Stanford Coronary Risk Intervention Project baseline survey. Metab Clin Exp. 44: 106114.
  • 12
    Diehl, A. K., Fuller, J. H., Mattock, M. B., Salter, A. M., el Gohari, R., Keen, H. (1988) The relationship of high density lipoprotein subfractions to alcohol consumption, other lifestyle factors, and coronary heart disease. Atherosclerosis. 69: 14553.
  • 13
    von Eckardstein, A., Assmann, G. (2001) Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol. 11: 627637.
  • 14
    Robins, SJ. (2001) Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol. 88: 19N23N.
  • 15
    Despres, J. P., Moorjani, S., Lupien, P. J., Tremblay, A., Nadeau, A., Bouchard, C. (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arterioscler. 10: 497511.
  • 16
    Campfield, L. A., Smith, F. J., Burn, P. (1998) Strategies and potential molecular targets for obesity treatment. Science. 280: 13831387.
  • 17
    Hubert, H. B., Feinleib, M., McNamara, P. M., Castelli, WP. (1983) Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 67: 968977.
  • 18
    Killeen, J., Vanderburg, D., Harlan, WR. (1978) Application of weight- height ratios and body indices to juvenile populations—the National Health Examination Survey Data. J Chronic Dis. 31: 529537.
  • 19
    Toth, PP. (2005) High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol. 96: 50K58K.
  • 20
    Glueck, C. J., Taylor, H. L., Jacobs, D., Morrison, J. A., Beaglehole, R., Williams, OD. (1980) Plasma high density lipoprotein cholesterol: association with measurements of body mass. Circulation. 62 (Suppl IV): IV629.
  • 21
    Lamon-Fava, S., Wilson, P. W., Schaefer, EJ. (1996) Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 16: 150915.
  • 22
    Larsson, B., Svardsudd, K., Welin, L., Wilhelmsen, L., Björntorp, P., Tibblin, G. (1984) Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 288: 14011404.
  • 23
    Peiris, A. N., Sothmann, M. S., Hoffmann, R. G., et al (1989) Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med. 110: 86772.
  • 24
    Kissebah, A. H., Alfarsi, S., Adams, PW. (1981) Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metab Clin Exp. 30: 856868.
  • 25
    Ostlund, R. E., Jr, Staten, M., Kohrt, W. M., Schultz, J., Malley, M. (1990) The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N Engl J Med. 322: 229234.
  • 26
    Despres, J. P., Moorjani, S., Ferland, M., et al (1989) Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis. 9: 20310.
  • 27
    Kissebah, A. H., Vydelingum, N., Murray, R., et al (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 54: 254260.
  • 28
    Nicklas, B. J., Penninx, B. W., Ryan, A. S., Berman, D. M., Lynch, N. A., Dennis, KE. (2003) Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care. 26: 14131420.
  • 29
    Despres, J. P., Couillard, C., Gagnon, J., et al (2000) Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 20: 19321938.
  • 30
    Lear, S. A., Toma, M., Birmingham, C. L., Frohlich, JJ. (2003) Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 52: 12951301.
  • 31
    Schmitz, G., Lackner, KJ. (1993) High-density lipoproteins and atherosclerosis. Curr Opin Lipidol. 4: 392400.
  • 32
    Dobiasova, M., Frohlich, J. (1998) Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL-cholesterol ratio. Physiol Res. 47: 38797.
  • 33
    Bertiere, M. C., Fumeron, F., Rigaud, D., Malon, D., Apfelbaum, M., Girard-Globa, A. (1988) Low high density lipoprotein-2 concentrations in obese male subjects. Atherosclerosis. 73: 5761.
  • 34
    Carr, M. C., Hokanson, J. E., Zambon, A., et al (2001) The contribution of intra-abdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab. 86: 28312837.
  • 35
    Miller, NE. (1987) Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J. 113: 589597.
  • 36
    Patsch, J. R., Prasad, S., Gotto, A. M., Jr, Bengtsson-Olivecrona, G. (1984) Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J Clin Invest. 74: 201723.
  • 37
    Despres, J. P., Ferland, M., Moorjani, S., et al (1989) Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL-cholesterol in obese women. Arteriosclerosis. 9: 485492.
  • 38
    Patsch, J. R., Karlin, J. B., Scott, L. W., Smith, L. C., Gotto, A. M., Jr (1983) Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA. 80: 144953.
  • 39
    Tall, AR. (1990) Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86: 37984.
  • 40
    Ginsberg, HN. (2000) Insulin resistance and cardiovascular disease. J Clin Invest. 106: 453458.
  • 41
    Coppack, S. W., Evans, R. D., Fisher, R. M., et al (1992) Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metab Clin Exp. 41: 264272.
  • 42
    Haemmerle, G., Zimmermann, R., Zechner, R. (2003) Letting lipids go: hormone-sensitive lipase. Curr Opin Lipidol. 14: 289297.
  • 43
    Murakami, T., Michelagnoli, S., Longhi, R., et al (1995) Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol. 15: 18191828.
  • 44
    Arai, T., Yamashita, S., Hirano, K., et al (1994) Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL-cholesterol levels in obesity. Arterioscler Thromb. 14: 112936.
  • 45
    McLaughlin, T., Abbasi, F., Lamendola, C., Reaven, G. (2007) Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 167: 642648.
  • 46
    Sorbris, R., Petersson, B. G., Nilsson-Ehle, P. (1981) Effects of weight reduction on plasma lipoproteins and adipose tissue metabolism in obese subjects. Eur J Clin Invest. 11: 491498.
  • 47
    McKenney, J. M., Davidson, M. H., Shear, C. L., Revkin, JH. (2006) Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 48: 17821790.
  • 48
    Clark, R. W., Ruggeri, R. B., Cunningham, D., Bamberger, MJ. (2006) Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 47: 537552.
  • 49
    Carr, M. C., Ayyobi, A. F., Murdoch, S. J., Deeb, S. S., Brunzell, JD. (2002) Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol. 22: 667673.
  • 50
    Foger, B., Ritsch, A., Doblinger, A., Wessels, H., Patsch, JR. (1996) Relationship of plasma cholesteryl ester transfer protein to HDL-cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 16: 14306.
  • 51
    Borggreve, S. E., De Vries, R., Dullaart, RP. (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest. 33: 10511069.
  • 52
    Berenson, A. (2006) End of trial is a big loss for Pfizer and heart patients. New York Times. 4: A26.
  • 53
    Hamilton, J. A., Deckelbaum, RJ. (2007) Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease? Nat Struct Mol Biol. 14: 9597.
  • 54
    Howes, L. G., Kostner, K. (2007) The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs. 16: 15091516.
  • 55
    Qiu, X., Mistry, A., Ammirati, M. J., et al (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 14: 106113.
  • 56
    Jahangiri, A., Rader, D. J., Marchadier, D., Curtiss, L. K., Bonnet, D. J., Rye, KA. (2005) Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res. 46: 896903.
  • 57
    Paradis, M. E., Badellino, K. O., Rader, D. J., et al (2006) Visceral adiposity and endothelial lipase. J Clin Endocrinol Metab. 91: 35383543.
  • 58
    Zimmermann, R., Strauss, J. G., Haemmerle, G., et al (2004) Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 306: 13831386.
  • 59
    Schweiger, M., Schreiber, R., Haemmerle, G., et al (2006) Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism. J Biol Chem. 281: 4023640241.
  • 60
    Langin, D., Dicker, A., Tavernier, G., et al (2005) Adipocyte lipases and defect of lipolysis in human obesity. Diabetes. 54: 31903197.
  • 61
    Jocken, J. W., Langin, D., Smit, E., et al (2007) Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. J Clin Endocrinol Metab. 92: 22922299.
  • 62
    Jauhiainen, M., Metso, J., Pahlman, R., Blomqvist, S., van Tol, A., Ehnholm, C. (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 268: 40324036.
  • 63
    Marques-Vidal, P., Jauhiainen, M., Metso, J., Ehnholm, C. (1997) Transformation of high density lipoprotein 2 particles by hepatic lipase and phospholipid transfer protein. Atherosclerosis. 133: 8795.
  • 64
    Dullaart, R. P., Sluiter, W. J., Dikkeschei, L. D., Hoogenberg, K., van Tol, A. (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 24: 188194.
  • 65
    Kaser, S., Laimer, M., Sandhofer, A., Salzmann, K., Ebenbichler, C. F., Patsch, JR. (2004) Effects of weight loss on PLTP activity and HDL particle size. Int J Obes Relat Metab Disord. 28: 12801282.
  • 66
    Williams, P. T., Wood, P. D., Krauss, R. M., et al (1983) Does weight loss cause the exercise-induced increase in plasma high density lipoproteins? Atherosclerosis. 47: 173185.
  • 67
    Wolf, R. N., Grundy, SM. (1980) Effects of caloric restriction on plasma lipids and lipoproteins. Clin Res. 28: 55a.
  • 68
    Fong, B. S., Rodrigues, P. O., Salter, A. M., et al (1985) Characterization of high density lipoprotein binding to human adipocyte plasma membranes. J Clin Invest. 75: 18041812.
  • 69
    Despres, J. P., Fong, B. S., Julien, P., Jimenez, J., Angel, A. (1987) Regional variation in HDL metabolism in human fat cells: effect of cell size. Am J Physiol. 252: E654E659.
  • 70
    Schwartz, RS. (1987) The independent effects of dietary weight loss and aerobic training on high density lipoproteins and apolipoprotein A-I concentrations in obese men. Metabolism. 36: 165171.
  • 71
    Maciejko, J. J., Holmes, D. R., Kottke, B. A., Zinsmeister, A. R., Dinh, D. M., Mao, SJ. (1983) Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 309: 385389.
  • 72
    Kunitake, S. T., La Sala, K. J., Kane, JP. (1985) Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 26: 549555.
  • 73
    Garrison, R. J., Wilson, P. W., Castelli, W. P., Feinleib, M., Kannel, W. B., McNamara, PM. (1980) Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism. 29: 10531060.
  • 74
    Oram, JF. (1983) Effects of high density lipoprotein subfractions on cholesterol homeostasis in human fibroblasts and arterial smooth muscle cells. Arteriosclerosis. 3: 420432.
  • 75
    Khoo, J. C., Miller, E., McLoughlin, P., Steinberg, D. (1990) Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I. J Lipid Res. 31: 645652.
  • 76
    Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., Clift, SM. (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353: 265267.
  • 77
    Brinton, E. A., Eisenberg, S., Breslow, JL. (1991) Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 87: 536544.
  • 78
    Gylling, H., Vega, G. L., Grundy, SM. (1992) Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res. 33: 15271539.
  • 79
    Ooi, E. M., Watts, G. F., Farvid, M. S., et al (2005) High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res. 13: 10081016.
  • 80
    Brinton, E. A., Eisenberg, S., Breslow, JL. (1989) Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women. J Clin Invest. 84: 262269.
  • 81
    Brinton, E. A., Eisenberg, S., Breslow, JL. (1990) A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest. 85: 144151.
  • 82
    Brinton, E. A., Terry, JG. (1996) Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of lp A-I in postmenopausal women. Circulation. 94 (Suppl): I266.
  • 83
    Dullaart, R. P., Sluiter, W. J., Dikkeschei, L. D., Hoogenberg, K., Van Tol, A. (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest. 24: 188194.
  • 84
    Deeb, S. S., Zambon, A., Carr, M. C., Ayyobi, A. F., Brunzell, JD. (2003) Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res. 44: 12791286.
  • 85
    Rashid, S., Barrett, P. H., Uffelman, K. D., Watanabe, T., Adeli, K., Lewis, GF. (2002) Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 22: 483487.
  • 86
    Rashid, S., Uffelman, K., Lewis, GF. (2002) The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications. 16: 2428.
  • 87
    Sasahara, T., Yamashita, T., Sviridov, D., Fidge, N., Nestel, P. (1997) Altered properties of high density lipoprotein subfractions in obese subjects. J Lipid Res. 38: 600611.
  • 88
    Krimbou, L., Marcil, M., Genest, J. (2006) New insights into the biogenesis of human high-density lipoproteins. Curr Opin Lipidol. 17: 258267.
  • 89
    Krimbou, L., Hajj, H. H., Blain, S., et al (2005) Biogenesis and speciation of nascent apoA-I-containing particles in various cell lines. J Lipid Res. 46: 16681677.
  • 90
    Francone, O. L., Gurakar, A., Fielding, C. (1989) Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem. 264: 706672.
  • 91
    Huang, Y., von Eckardstein, A., Assmann, G. (1993) Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb. 13: 445458.
  • 92
    Kaser, S., Sandhofer, A., Foger, B., et al (2001) Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia. 44: 11111117.
  • 93
    Sasahara, T., Nestel, P., Fidge, N., Sviridov, D. (1998) Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects. J Lipid Res. 39: 544554.
  • 94
    Miida, T., Nakamura, Y., Inano, K., et al (1996) Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem. 42: 19921995.
  • 95
    Padwal, R. S., Majumdar, SR. (2007) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 369: 7177.
  • 96
    Hauptman, J. B., Jeunet, F. S., Hartmann, D. (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin). Am J Clin Nutr. 55 (1 Suppl): 309S13S.
  • 97
    Padwal, R., Li, S. K., Lau, DC. (2004) Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 4: CD004094.
  • 98
    Padwal, R., Li, S. K., Lau, DC. (2003) Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 27: 14371446.
  • 99
    Nisoli, E., Carruba, MO. (2000) An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 1: 127139.
  • 100
    Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 295: 761775.
  • 101
    Henness, S., Robinson, D. M., Lyseng-Williamson, KA. (2006) Rimonabant. Drugs. 66: 21092119.
  • 102
    Wolf, R. N., Grundy, SM. (1983) Influence of weight reduction on plasma lipoproteins in obese patients. Arteriosclerosis. 3: 160169.
  • 103
    Rossner, S., Bjorvell, H. (1987) Early and late effects of weight loss on lipoprotein metabolism in severe obesity. Atherosclerosis. 64: 125130.
  • 104
    Seshadri, P., Iqbal, N., Stern, L., et al (2004) A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 117: 398405.
  • 105
    Wood, P. D., Stefanick, M. L., Dreon, D. M., et al (1988) Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med. 319: 11731179.
  • 106
    Williams, P. T., Krauss, R. M., Vranizan, K. M., Wood, PD. (1990) Changes in lipoprotein subfractions during diet-induced and exercise-induced weight loss in moderately overweight men. Circulation. 81: 12931304.
  • 107
    Wood, P. D., Stefanick, M. L., Williams, P. T., Haskell, WL. (1991) The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med. 325: 461466.
  • 108
    Hayek, T., Ito, Y., Azrolan, N., et al (1993) Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL-cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest. 91: 166571.
  • 109
    Williams, PT. (November 811, 1993) Lipoproteins and adiposity show improvement at substantially higher exercise levels than those currently recommended. American Heart Association Conference 66th Scientific Sessions: Atlanta, GA.
  • 110
    Leon, A. S., Conrad, J., Hunninghake, D. B., Serfass, R. (1979) Effects of a vigorous walking program on body composition, and carbohydrate and lipid metabolism of obese young men. Am J Clin Nutr. 32: 17761787.
  • 111
    Lewis, S., Haskell, W. L., Wood, P. D., Manoogian, N., Bailey, J. E., Pereira, MB. (1976) Effects of physical activity on weight reduction in obese middle-aged women. Am J Clin Nutr. 29: 151156.
  • 112
    Thompson, PD. (1990) What do muscles have to do with lipoproteins? Circulation. 81: 14281430.
  • 113
    Brownell, K. D., Bachorik, P. S., Ayerle, RS. (1982) Changes in plasma lipid and lipoprotein levels in men and women after a program of moderate exercise. Circulation. 65: 477484.
  • 114
    Swank, A. M., Robertson, R. J., Deitrich, R. W., Bates, M. (1987) The effect of acute exercise on high density lipoprotein-cholesterol and the subfractions in females. Atherosclerosis. 63: 187192.
  • 115
    Kantor, M. A., Cullinane, E. M., Herbert, P. N., Thompson, PD. (1984) Acute increase in lipoprotein lipase following prolonged exercise. Metabolism. 33: 454457.
  • 116
    Herbert, P. N., Bernier, D. N., Cullinane, E. M., Edelstein, L., Kantor, M. A., Thompson, PD. (1984) High-density lipoprotein metabolism in runners and sedentary men. JAMA. 252: 10341037.
  • 117
    Reisin, E., Frohlich, E. D., Messerli, F. H., et al (1983) Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med. 98: 315319.
  • 118
    Sopko, G., Leon, A. S., Jacobs, D. R., Jr, et al (1985) The effects of exercise and weight loss on plasma lipids in young obese men. Metabolism. 34: 227236.
  • 119
    Martin, J. E., Dubbert, PM. (1982) Exercise applications and promotion in behavioral medicine: current status and future directions. J Consult Clin Psychol. 50: 10041017.
  • 120
    Kiens, B., Lithell, H. (1989) Lipoprotein metabolism influenced by training-induced changes in human skeletal muscle. J Clin Invest. 83: 558564.
  • 121
    Schwartz, R. S., Brunzell, JD. (1981) Increase of adipose tissue lipoprotein lipase activity with weight loss. J Clin Invest. 67: 14251430.
  • 122
    Mohanka, M., Irwin, M., Heckbert, S. R., et al (2006) Serum lipoproteins in overweight/obese postmenopausal women: a one-year exercise trial. Med Sci Sports Exerc. 38: 231239.
  • 123
    Park, S. K., Park, J. H., Kwon, Y. C., Kim, H. S., Yoon, M. S., Park, HT. (2003) The effect of combined aerobic and resistance exercise training on abdominal fat in obese middle-aged women. J Physiol Anthropol Appl Human Sci. 22: 129135.
  • 124
    Williams, P. T., Wood, P. D., Haskell, W. L., Vranizan, K. (1982) The effects of running mileage and duration on plasma lipoprotein levels. JAMA. 247: 26742679.
  • 125
    Williams, PT. (1990) Weight set-point theory and the high-density lipoprotein concentrations of long-distance runners. Metabolism. 39: 460467.
  • 126
    Thompson, P. D., Yurgalevitch, S. M., Flynn, M. M., et al (1997) Effect of prolonged exercise training without weight loss on high-density lipoprotein metabolism in overweight men. Metabolism. 46: 217223.
  • 127
    Thompson, P. D., Cullinane, E. M., Sady, S. P., et al (1988) Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation. 78: 2534.
  • 128
    Rifkind, BM. (1987) Gemfibrozil, lipids, and coronary risk. N Engl J Med. 317: 12791281.
  • 129
    Wing, R. R., Jeffery, RW. (1979) Outpatient treatments of obesity: a comparison of methodology and clinical results. Int J Obes Relat Metab Disord. 3: 261279.